SM
ABCL icon

SB Management’s AbCellera Biologics ABCL Stock Holding History

SB Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,764,299
Closed -$75.7M – 1
2022
Q1 		$75.7M Sell
7,764,299
-2,052,891
-21% -$19.4M 14.68% 3
2021
Q4 		$140M Hold
9,817,190
– – 13.88% 3
2021
Q3 		$197M Hold
9,817,190
– – 20.16% 2
2021
Q2 		$216M Buy
9,817,190
+2,000,000
+26% +$55.2M 2.54% 5
2021
Q1 		$265M Buy
7,817,190
+1,050,000
+16% +$41.8M 1.71% 10
2020
Q4 		$272M Buy
+6,767,190
New +$309M 1.54% 9

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
Harvard Management Company
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

SB Management's ABCL Position: Q2 2022 in Review

SB Management sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 7,764,299 shares — an estimated $75.7M sold.

SB Management first reported a position in ABCL in Q4 2020 and held it in 6 quarters. The position peaked at $272M in Q4 2020. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

  • SB Management reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
  • SB Management sold 7,764,299 AbCellera Biologics shares in Q2 2022, an estimated $75.7M.
  • SB Management first reported a position in AbCellera Biologics in Q4 2020 and held it in 6 quarters.
  • SB Management's AbCellera Biologics position peaked at $272M in Q4 2020.
  • 161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on SB Management's 13F filing for Q2 2022.